To the Editor: We greatly appreciate the comments of Dr Lindor and colleagues in the letter titled "Preserving Personal Autonomy in a Genomic Testing Era" 1 regarding our approach to managing incidental findings from genome-scale sequencing. 2 We wholeheartedly agree that a consensus-based approach for determining how to handle the broad spectrum of incidental findings is unlikely to satisfy all constituents in the long term. Likewise, we are in complete agreement that patient preferences should play a central (although not exclusive) role in determining the return of results. Indeed, our "binning" approach attempts to balance the ethical responsibilities of the clinician (such as the duty to warn) with the autonomy of the patients to determine what information they want to know and what information they prefer not to know.
There are certainly many valid approaches to dividing the genome into categories that can be used to manage the return of incidental findings, but we strongly believe that some measure of clinical actionability will be a critical parameter in any successful strategy. In our approach, Bin 1 can be considered the category of incidental information in which the degree of clinical actionability invokes a duty to warn that supersedes patient preferences. Bin 2 contains the bulk of incidental information with limited clinical actionability that some patients may desire to know, whereas others may not, which is the very definition of individual informed decision making. Of course, there will be differing opinions about where to draw the line between Bin 1 and Bin 2, which is essentially the crux of the problem with consensus-based approaches to "binning" the genome. Instead, as pointed out by Lindor and colleagues, 1 there is a continuum of actionability.
We are therefore intrigued to hear about the efforts at the Mayo Center for Individualized Medicine to develop the Tailored Result Selection Tool with a scoring system for "actionability, " and we were gratified to see that our provisional bin assignments correlated reasonably well with the Mayo group's actionability scores. Our group has come to the very same conclusion that a semiquantitative measure is required to score the clinical actionability of gene-phenotype pairs in order to categorize them in a transparent and evidence-based fashion. We have focused on four key components of clinical actionability: (i) the severity of the threat to health for an undiagnosed individual carrying an incidentally identified deleterious allele; (ii) the likelihood that a serious threat will materialize, akin to penetrance; (iii) the effectiveness of interventions at preventing harm from occurring; and (iv) the acceptability in terms of the burdens or risks placed on the individual. These components of actionability have also been adopted as part of an evidencebased framework being developed by the Evaluation of Genomic Applications in Practice and Prevention working group 3 . Our local "binning" committee is now systematically scoring gene-phenotype pairs much in the same way as described by Lindor and colleagues.
1 In the process, we have revised the
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Letters to the editor We studied Avicenna's (Persian physician, 980-1037 AD) views on different aspects of medical genetics by reviewing his Canon of Medicine 4 and searched MEDLINE for relevant hereditary and congenital concepts and descriptions of temperament. We also investigated Zakhireh-kharazmshahi by Gorgani (a Persian physician inspired by Avicenna, 1041-1136 AD), 5 which is a comprehensive source in traditional medicine. Three main topics in the Canon, including temperament (Mizaj) and its uniqueness in each individual, hereditary and congenital disorders and their classification, and the rationalization for inborn malformations, foreshadow the development of the field of medical genetics. Considering the significance of temperament in traditional medicine, Avicenna emphasized the individuality of people based on their unique temperament, which would later correspond to the unique genetic makeup of each person and presage the central notion of interindividual variation so critical to the work of Darwin.
2 In addition, Avicenna discussed the congenital versus acquired nature of some disorders such as hearing loss and muscle problems in his book and, in some instances, described their severity and differences in more detail. 4 In discussing the transmission of diseases from person to person, he named six conditions, including premature baldness, under the category of hereditary transmissions.
6
Avicenna also classified congenital malformations into four categories: errors in form (such as broad head), errors in passages (such as stricture of the trachea), errors in cavities (cavities of the heart, for instance), and errors of surfaces (roughness and smoothness) ( Table 1) . 4 On the cause of deformities, he explained that some come into play from the beginning because of a defect in the formative 
